KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Other Working Capital Changes: 2017-2025

Historic Other Working Capital Changes for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Sep 2025 value amounting to $10.2 million.

  • Amneal Pharmaceuticals' Other Working Capital Changes rose 260.32% to $10.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.1 million, marking a year-over-year increase of 274.42%. This contributed to the annual value of $959,000 for FY2024, which is 102.54% up from last year.
  • According to the latest figures from Q3 2025, Amneal Pharmaceuticals' Other Working Capital Changes is $10.2 million, which was up 6.90% from $9.5 million recorded in Q2 2025.
  • Over the past 5 years, Amneal Pharmaceuticals' Other Working Capital Changes peaked at $115.3 million during Q2 2022, and registered a low of -$85.4 million during Q3 2022.
  • Its 3-year average for Other Working Capital Changes is -$1.5 million, with a median of -$1.1 million in 2024.
  • Examining YoY changes over the last 5 years, Amneal Pharmaceuticals' Other Working Capital Changes showed a top increase of 834.72% in 2022 and a maximum decrease of 2,535.58% in 2022.
  • Amneal Pharmaceuticals' Other Working Capital Changes (Quarterly) stood at -$5.5 million in 2021, then slumped by 703.01% to -$44.3 million in 2022, then skyrocketed by 70.62% to -$13.0 million in 2023, then spiked by 91.36% to -$1.1 million in 2024, then skyrocketed by 260.32% to $10.2 million in 2025.
  • Its last three reported values are $10.2 million in Q3 2025, $9.5 million for Q2 2025, and $513,000 during Q1 2025.